UNSPSC 51122403: Meprobamate/pentaerythritol tetranitrate

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV250. This VA Drug Class (CV250) classifies this compound as belonging to the group ANTIANGINALS.

UNSPSC 51122403 Meprobamate/pentaerythritol tetranitrate is a Commodity code that encompasses procurement of specific pharmaceutical products — primarily advanced life support medications, generic multi-source drugs, and over-the-counter products — by state and local health agencies, emergency services departments, and cooperative purchasing alliances. State and local governments buy under this code to stock emergency medical supplies for fire and rescue operations, support pharmacy benefit programs, and establish framework agreements for pharmaceutical distribution across multiple jurisdictions. Issuing bodies include municipal purchasing departments (notably the City of Tampa), state health and human services commissions (Texas HHS), and regional cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance / MMCAP). The mix reflects both direct emergency-services procurement and upstream supply-chain contracting through state-level cooperative vehicles that serve multiple state and local customers.

Recent activity spans Florida, Texas, and Minnesota. The City of Tampa issued an IFB (Solicitation 26P00188) on April 24, 2026, with a response deadline of April 8, 2026, seeking 370 units of Labetalol HCI 100mg vials, 1,810 units of Epinephrine 1:10,000 injections, 330 units of Adenosine 6mg vials, and 1,020 units of Diltiazem 25mg vials for Tampa Fire Rescue, with an estimated contract value of $40,000 and a five-percent bid discount for Small Local Business Enterprise participation. The Texas Health and Human Services Commission posted an RFI (HHS0017013) on April 3, 2026, gathering market intelligence on direct-to-manufacturer prescription programs and vendor capabilities for a future Therapeutic Pharmacy Initiative; this is exploratory procurement without stated dollar values or formal evaluation criteria. MMCAP, administered by the Minnesota Department of Administration, issued an RFP (S1070000015802) with a response deadline of March 26, 2026, to establish multi-award contracts for generic pharmaceuticals and OTC products distributed through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson), with pricing weighted at 75 percent and contract terms of two years effective July 1, 2026, extended to participating states including Oregon.